<DOC>
	<DOCNO>NCT00583362</DOCNO>
	<brief_summary>This continuation study evaluate long-term safety efficacy LymphoStat-B™ subject SLE disease , complete study LBSL02 benefit treatment .</brief_summary>
	<brief_title>A Continuation Trial Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02</brief_title>
	<detailed_description>The purpose continuation study evaluate long-term safety efficacy LymphoStat-B™ subject Systemic Lupus Erythematosus ( SLE ) , complete study LBSL02 benefit treatment .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Primary Inclusion Criteria 1 . Have complete LBSL02 trial achieve satisfactory response . Primary Exclusion Criteria 1 . Required 2 course corticosteroid treatment severe SLE flare last 5 month LBSL02 . 2 . Had SLE flare last 30 day LBSL02 1st dose LBSL99 . 3 . Used follow prohibited medication participation LBSL02 : Other investigational agent . Biologic therapeutic agent : adalimumab ( Humira™ ) , etanercept ( Enbrel™ ) , infliximab ( Remicade™ ) , rituximab ( Rituxan™ ) . Intravenous cyclophosphamide . Corticosteroids &gt; 100 mg/day prednisone equivalent reason severe SLE flare .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
</DOC>